FDA's Latest Guide: Drug Safety Reports, Now with Timely Clarity
Published Date: 12/16/2025
Notice
Summary
The FDA just released final rules to help drug study sponsors keep safety reports clear and on time for new drug and bioequivalence studies. If you’re running these studies, you’ll need to follow these updated safety reporting steps starting now to avoid delays or extra costs. This guidance makes safety checks easier and keeps everyone on the same page for safer medicines.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final guidance for IND safety reporting
If you run investigational new drug (IND) studies or IND‑exempt bioavailability/bioequivalence (BA/BE) studies, FDA issued a final guidance on December 16, 2025 with recommendations to help sponsors and sponsor‑investigators comply with expedited IND safety reporting (see 21 CFR 312.32 and 21 CFR 320.31(d)(3)). The guidance finalizes the June 28, 2021 draft and consolidates prior guidance to clarify sponsors' safety reporting responsibilities.
Revised aggregate analyses and rare disease guidance
The final guidance revises recommended approaches for aggregate analyses to reduce the need for unblinding when evaluating safety data. It also adds additional considerations specifically for small programs and rare disease studies.
Updated electronic submission information
The guidance provides updated information on electronic submission of IND safety reports, including references to electronic submission pathways such as the Electronic Submission Gateway and the Safety Reporting Portal. Related collections of information cited in the notice are approved under OMB control number 0910-0291.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17401, Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CABAZITAXEL (cabazitaxel) solution (injection), 60 milligrams (mg)/6 milliliters (mL) (10 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for Cabazitaxel (cabazitaxel) solution (injection), 60 mg/6 mL (10 mg/mL), if all other legal and regulatory requirements are met.
2026-17380, International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
The FDA is asking the public to share their thoughts on eight drugs that might get new international rules to control their use and abuse. This affects doctors, patients, and drug makers because it could change how these drugs are used medically or restricted worldwide. Comments are open until September 3, 2026, so jump in and have your say before the deadline!
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-22869, Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices; Guidance for Investigators, Industry, and Institutional Review Boards; Availability
The FDA just released final guidance to help researchers safely report problems with new drugs and devices during studies. This update affects clinical investigators, companies, and review boards by clarifying what safety info must be shared and when. The guidance is effective now, aiming to keep everyone on the same page without adding extra costs or delays.
Next: 2025-22871, Sunshine Act Meetings
The National Credit Union Administration is holding an open meeting on December 18, 2025, to talk about the Share Insurance Fund and the 2026-2027 budget. Credit unions and the public get a clear look at how money is managed and planned. This meeting keeps things transparent and on track for the coming years without any new costs announced.